144 related articles for article (PubMed ID: 36253718)
21. Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read.
Koenig M; Schulte-Altedorneburg G; Piontek M; Hentsch A; Spangenberg P; Schwenke C; Harders A; Heuser L
Eur Radiol; 2013 Dec; 23(12):3287-95. PubMed ID: 23824152
[TBL] [Abstract][Full Text] [Related]
22. [Safety and use of gadobutrol in patients with brain tumors (phase III trial)].
Lemke AJ; Sander B; Balzer T; Geens V; Hosten N; Felix R
Rofo; 1997 Dec; 167(6):591-8. PubMed ID: 9465954
[TBL] [Abstract][Full Text] [Related]
23. Use of half-dose gadolinium-enhanced MRI and magnetization transfer saturation in brain tumors.
Haba D; Pasco Papon A; Tanguy JY; Burtin P; Aube C; Caron-Poitreau C
Eur Radiol; 2001; 11(1):117-22. PubMed ID: 11194902
[TBL] [Abstract][Full Text] [Related]
24. Focal liver lesions: detection and characterization at double-contrast liver MR Imaging with ferucarbotran and gadobutrol versus single-contrast liver MR imaging.
Heilmaier C; Lutz AM; Bolog N; Weishaupt D; Seifert B; Willmann JK
Radiology; 2009 Dec; 253(3):724-33. PubMed ID: 19789232
[TBL] [Abstract][Full Text] [Related]
25. Renal metastasis. Detection and characterization on enhanced magnetic resonance imaging using an animal model.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1997 Apr; 32(4):212-7. PubMed ID: 9101356
[TBL] [Abstract][Full Text] [Related]
26. Multiple Administrations of Gadobutrol in the Pediatric Brain: No Change in T1 Signal at MRI.
Bhargava R; Persad ARL; Bhargava NK; Hawkes M
Radiology; 2018 Oct; 289(1):204-209. PubMed ID: 29944079
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T.
Morelli JN; Runge VM; Vu L; Loynachan AT; Attenberger UI
Invest Radiol; 2010 Dec; 45(12):810-8. PubMed ID: 20856127
[TBL] [Abstract][Full Text] [Related]
28. Effect of at Least 10 Serial Gadobutrol Administrations on Brain Signal Intensity Ratios on T1-Weighted MRI in Children: A Matched Case-Control Study.
Ozturk K; Nascene D
AJR Am J Roentgenol; 2021 Sep; 217(3):753-760. PubMed ID: 33112200
[No Abstract] [Full Text] [Related]
29. Comparison of Unenhanced T1-Weighted Signal Intensities Within the Dentate Nucleus and the Globus Pallidus After Serial Applications of Gadopentetate Dimeglumine Versus Gadobutrol in a Pediatric Population.
Renz DM; Kümpel S; Böttcher J; Pfeil A; Streitparth F; Waginger M; Reichenbach JR; Teichgräber UK; Mentzel HJ
Invest Radiol; 2018 Feb; 53(2):119-127. PubMed ID: 28976476
[TBL] [Abstract][Full Text] [Related]
30. Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system.
Gutierrez JE; Rosenberg M; Duhaney M; Simon JA; Brueggenwerth G; Agris JM; Knopp EA
J Magn Reson Imaging; 2015 Mar; 41(3):788-96. PubMed ID: 24578298
[TBL] [Abstract][Full Text] [Related]
31. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).
Seidl Z; Vymazal J; Mechl M; Goyal M; Herman M; Colosimo C; Pasowicz M; Yeung R; Paraniak-Gieszczyk B; Yemen B; Anzalone N; Citterio A; Schneider G; Bastianello S; Ruscalleda J
AJNR Am J Neuroradiol; 2012 Jun; 33(6):1050-8. PubMed ID: 22383237
[TBL] [Abstract][Full Text] [Related]
32. Repeated intravenous administration of gadobutrol does not lead to increased signal intensity on unenhanced T1-weighted images-a voxel-based whole brain analysis.
Langner S; Kromrey ML; Kuehn JP; Grothe M; Domin M
Eur Radiol; 2017 Sep; 27(9):3687-3693. PubMed ID: 28289935
[TBL] [Abstract][Full Text] [Related]
33. Glymphatic MRI in idiopathic normal pressure hydrocephalus.
Ringstad G; Vatnehol SAS; Eide PK
Brain; 2017 Oct; 140(10):2691-2705. PubMed ID: 28969373
[TBL] [Abstract][Full Text] [Related]
34. Gadobutrol in the central nervous system at three doses: results from a phase II, randomized, multicenter trial.
Breuer J; Gutierrez J; Latchaw R; Lehr R; Sorensen AG
J Magn Reson Imaging; 2014 Feb; 39(2):410-8. PubMed ID: 23681501
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of the efficacy of gadobutrol and multihance in contrast-enhanced MRI for diagnosis of brain metastasis in lung cancer].
Li ZL; Chen X; Xia CC; Sun JY; Li CX; Tang HH; Song B
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jul; 43(4):601-4. PubMed ID: 22997905
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of plaque detection and optimum time of enhancement in acute attack multiple sclerosis after contrast injection.
Hashemi H; Behzadi S; Ghanaati H; Harirchian MH; Yaghoobi M; Shakiba M; Jalali AH; Firouznia K
Acta Radiol; 2014 Mar; 55(2):218-24. PubMed ID: 23975149
[TBL] [Abstract][Full Text] [Related]
37. Dynamic contrast-enhanced MR imaging of the prostate: intraindividual comparison of gadoterate meglumine and gadobutrol.
Lee CH; Vellayappan B; Taupitz M; Hamm B; Asbach P
Eur Radiol; 2019 Dec; 29(12):6982-6990. PubMed ID: 31264013
[TBL] [Abstract][Full Text] [Related]
38. MR enhancement of brain lesions: increased contrast dose compared with magnetization transfer.
Knauth M; Forsting M; Hartmann M; Heiland S; Balzer T; Sartor K
AJNR Am J Neuroradiol; 1996; 17(10):1853-9. PubMed ID: 8933869
[TBL] [Abstract][Full Text] [Related]
39. Intravenous injection of gadobutrol in an epidemiological study group did not lead to a difference in relative signal intensities of certain brain structures after 5 years.
Kromrey ML; Liedtke KR; Ittermann T; Langner S; Kirsch M; Weitschies W; Kühn JP
Eur Radiol; 2017 Feb; 27(2):772-777. PubMed ID: 27221561
[TBL] [Abstract][Full Text] [Related]
40. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T.
Attenberger UI; Runge VM; Jackson CB; Baumann S; Birkemeier K; Michaely HJ; Schoenberg SO; Reiser MF; Wintersperger BJ
Invest Radiol; 2009 May; 44(5):251-6. PubMed ID: 19550376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
